Who are Cisplatin/carboplatin plus etoposide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CEV chemotherapy, Flu/Cy/ATG or Cy/ATG, chemotherapy plus p53, SOX Chemotherapy, FEC, gemcitabine, cisplatin and bevacizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cisplatin-carboplatin-plus-etoposide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cisplatin/carboplatin plus etoposide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cisplatin/carboplatin plus etoposide (Cisplatin/carboplatin plus etoposide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy. Area: Oncology.

phase 3 Combination chemotherapy DNA (platinum agents); Topoisomerase II (etoposide) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cisplatin/carboplatin plus etoposide (Cisplatin/carboplatin plus etoposide) — EpicentRx, Inc.. This combination uses platinum-based chemotherapy agents (cisplatin or carboplatin) to cross-link DNA, combined with etoposide, a topoisomerase II inhibitor that prevents DNA unwinding and repair.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Cisplatin/carboplatin plus etoposide TARGET	Cisplatin/carboplatin plus etoposide	EpicentRx, Inc.	phase 3	Combination chemotherapy	DNA (platinum agents); Topoisomerase II (etoposide)
CEV chemotherapy	CEV chemotherapy	Sun Yat-sen University	marketed	Combination chemotherapy regimen
Flu/Cy/ATG or Cy/ATG	Flu/Cy/ATG or Cy/ATG	Peking University People's Hospital	marketed	Conditioning regimen (combination chemotherapy and immunosuppressive therapy)
chemotherapy plus p53	chemotherapy plus p53	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Combination chemotherapy with p53 gene therapy	p53 tumor suppressor protein
SOX Chemotherapy	SOX Chemotherapy	The First Affiliated Hospital with Nanjing Medical University	marketed	Combination chemotherapy regimen
FEC	FEC	Hoffmann-La Roche	marketed	Combination chemotherapy regimen
gemcitabine, cisplatin and bevacizumab	gemcitabine, cisplatin and bevacizumab	Fundacion Clinic per a la Recerca Biomédica	marketed	Combination chemotherapy with anti-angiogenic monoclonal antibody	DNA (gemcitabine, cisplatin); VEGF (bevacizumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy class)

Children's Cancer Group, China · 1 drug in this class
EpicentRx, Inc. · 1 drug in this class
Sumitomo Pharma (Suzhou) Co., Ltd. · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cisplatin/carboplatin plus etoposide — Competitive Intelligence Brief. https://druglandscape.com/ci/cisplatin-carboplatin-plus-etoposide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab